Literature DB >> 26626206

Small interfering RNA silencing of interleukin-6 in mesenchymal stromal cells inhibits multiple myeloma cell growth.

Hoon Koon Teoh1, Pei Pei Chong2, Maha Abdullah2, Zamberi Sekawi2, Geok Chin Tan3, Chooi Fun Leong3, Soon Keng Cheong4.   

Abstract

Studies demonstrated that mesenchymal stromal cells (MSC) from bone marrow stroma produced high concentration of interleukin-6 (IL-6) that promoted multiple myeloma cell growth. In view of the failure of IL-6 monoclonal antibody therapy to demonstrate substantial clinical responses in early clinical trials, more effective methods are needed in order to disrupt the favourable microenvironment provided by the bone marrow stroma. In this study, we evaluated the short interfering RNA (siRNA)-mediated silencing of IL-6 in MSC and the efficacy of these genetically modified MSC, with IL-6 suppression, on inhibition of U266 multiple myeloma cell growth. IL-6 mRNA and protein were significantly suppressed by 72h post IL-6 siRNA transfection without affecting the biological properties of MSC. Here we show significant inhibition of cell growth and IL-6 production in U266 cells co-cultured with MSC transfected with IL-6 siRNA when compared to U266 cells co-cultured with control MSC. We also show that the tumour volume and mitotic index of tumours in nude mice co-injected with U266 and MSC transfected with IL-6 siRNA were significantly reduced compared to tumours of mice co-injected with control MSC. Our results suggest potential use of RNA interference mediated therapy for multiple myeloma.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Interleukin-6; Mesenchymal stromal cells; Multiple myeloma; RNA interference; siRNA

Mesh:

Substances:

Year:  2015        PMID: 26626206     DOI: 10.1016/j.leukres.2015.10.004

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  8 in total

Review 1.  New Challenge: Mitochondrial Epigenetics?

Authors:  Martin Stimpfel; Nina Jancar; Irma Virant-Klun
Journal:  Stem Cell Rev Rep       Date:  2018-02       Impact factor: 5.739

2.  Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse.

Authors:  Adam Nowakowski; Katarzyna Drela; Justyna Rozycka; Miroslaw Janowski; Barbara Lukomska
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

Review 3.  Multiple myeloma in the marrow: pathogenesis and treatments.

Authors:  Heather Fairfield; Carolyne Falank; Lindsey Avery; Michaela R Reagan
Journal:  Ann N Y Acad Sci       Date:  2016-01       Impact factor: 5.691

4.  Mesenchymal Stem Cells Inhibit the Effects of Dexamethasone in Multiple Myeloma Cells.

Authors:  Mingyang Deng; Huan Yuan; Hongling Peng; Sufang Liu; Xiang Xiao; Zhihua Wang; Guangsen Zhang; Han Xiao
Journal:  Stem Cells Int       Date:  2022-04-04       Impact factor: 5.443

Review 5.  Mesenchymal Stem Cells as a Prospective Therapy for the Diabetic Foot.

Authors:  Qinan Wu; Bing Chen; Ziwen Liang
Journal:  Stem Cells Int       Date:  2016-10-27       Impact factor: 5.443

6.  Silencing of augmenter of liver regeneration inhibited cell proliferation and triggered apoptosis in U266 human multiple myeloma cells.

Authors:  H Q Zeng; Y Luo; S F Lou; Q Liu; L Zhang; J C Deng
Journal:  Braz J Med Biol Res       Date:  2017-08-31       Impact factor: 2.904

Review 7.  Mesenchymal stem cells: A new therapeutic tool for chronic kidney disease.

Authors:  Jiali Wang; Yongda Lin; Xiutian Chen; Yiping Liu; Tianbiao Zhou
Journal:  Front Cell Dev Biol       Date:  2022-10-04

8.  XRK3F2 Inhibition of p62-ZZ Domain Signaling Rescues Myeloma-Induced GFI1-Driven Epigenetic Repression of the Runx2 Gene in Pre-osteoblasts to Overcome Differentiation Suppression.

Authors:  Juraj Adamik; Rebecca Silbermann; Silvia Marino; Quanhong Sun; Judith L Anderson; Dan Zhou; Xiang-Qun Xie; G David Roodman; Deborah L Galson
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-29       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.